Patent ID: 8765745

Claim:
A method for the treatment of an immune-related disease in a patient wherein the immune-related disease is selected from the group consisting of Sjogren's syndrome, rheumatoid arthritis, transplant rejection, and graft versus host disease, the method comprising administering to the patient a compound having a structure of formula (I) or a pharmaceutically acceptable salt thereof, wherein each A is independently selected from C═O, C═S, and SO 2 ; or A is optionally a covalent bond when adjacent to an occurrence of Z; B is absent or is N(R 9 )R 10 ; L is absent or is selected from C═O, C═S, and SO 2 ; M is C 1-2 alkyl; Q is absent or is selected from O, NH, and N—C 1-6 alkyl; X is selected from O, S, NH, and N—C 1-6 alkyl; each Z is independently selected from O, S, NH, and N—C 1-6 alkyl; or Z is optionally a covalent bond when adjacent to an occurrence of A; R 1 is selected from H, —C 1-6 alkyl-B, C 1-6 hydroxyalkyl, C 1-6 alkoxyalkyl, aryl, and C 1-6 aralkyl; R 2 and R 3 are each independently selected from aryl, C 1-6 aralkyl, heteroaryl, and C 1-6 heteroaralkyl; R 4 is N(R 5 )L-Q-R 6 ; R 5 is selected from hydrogen, OH, aryl C 1-6 alkyl, and C 1-6 alkyl; R 6 is selected from an N-terminal protecting group, heterocyclylMZAZC 1-6 alkyl-, heterocyclylM-, and carbocyclylM; R 7 and R 8 are independently selected from hydrogen, C 1-6 alkyl, and C 1-6 aralkyl; R 9 is selected from hydrogen, OH, and C 1-6 alkyl; and R 10 is an N-terminal protecting group; and R 15 is selected from C 1-6 alkyl and C 1-6 hydroxyalkyl; provided that in any occurrence of the sequence ZAZ, at least one member of the sequence must be other than a covalent bond.